An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;, BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, in combination with dabrafenib;

No related papers found yet.

None listed